During its January 2024 meeting, the European Medicine Agency’s CHMP reviewed six recommendations for eligibility to PRIME. Two were granted and four were denied. Among the two granted eligibility was Sangamo’s isaralgagene civaparvovec for the treatment of Fabry disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>